Although in vitro data supports that leptin-induced aggrecan downregulation is implicated in obesity-associated IDD, further experiments are needed to differentiate the effect of hyperleptinemia from those arising from other metabolic deregulations in obesity. Here, ACAN is linked to Obesity.